SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...

AnaptysBio is splitting into a high-margin royalty company and a pipeline-focused biopharma, each with distinct valuation ...

Stifel on Tuesday initiated coverage of Summit Therapeutics Inc. SMMT, citing the potential of its lead drug candidate, ...

Black Diamond Therapeutics, Inc. BDTX offers a high-leverage oncology setup built around one primary value driver: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor ...

BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.

A new review reveals how focal adhesion kinase (FAK) acts as a central regulator of tumor progression and immune suppression ...

A new comprehensive review is shedding light on the expanding role of focal adhesion kinase (FAK) in cancer biology and its potential as a ...

Rigel Pharmaceuticals' Gavreto acquisition materially boosted revenue and is valued at ~$245M NPV, about half of RIGL's ...

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...

EQT Life Sciences is pleased to announce that the LSP 7 fund ("EQT Life Sciences") has exited its minority stake in Tubulis (the "Company"), a Germany-based, clinical-stage biotechnology company ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a ...

Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer’s antibody–drug conjugate (ADC) capabilities with a ...